Role of IL-9 and IL-10 in the pathogenesis of chronic spontaneous urticaria through the JAK/STAT signalling pathway.
Adult
Animals
CD4-Positive T-Lymphocytes
/ pathology
CD8-Positive T-Lymphocytes
/ immunology
Chronic Urticaria
/ immunology
Female
Humans
Interferon-gamma
Interleukin-10
/ immunology
Interleukin-9
/ immunology
Janus Kinase 2
/ immunology
Male
Mice
Middle Aged
STAT3 Transcription Factor
/ immunology
Signal Transduction
/ immunology
JAK/STAT signalling pathway
chronic spontaneous urticaria
inflammation
interleukin-10
interleukin-9
Journal
Cell biochemistry and function
ISSN: 1099-0844
Titre abrégé: Cell Biochem Funct
Pays: England
ID NLM: 8305874
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
28
08
2019
revised:
17
10
2019
accepted:
15
12
2019
pubmed:
29
1
2020
medline:
6
1
2021
entrez:
29
1
2020
Statut:
ppublish
Résumé
This study investigated the role of interleukin (IL)-9 and IL-10 in the pathogenesis of chronic spontaneous urticaria (CSU). Autologous serum skin test and histamine release test were performed in CSU patients and normal subjects. Kunming mice were used to develop a mouse model for CSU. We induced IL-9 overexpression, IL-10 overexpression, and JAK/STAT pathway inhibition as well as a combination of all three conditions in CSU and control mice. Eosinophils in the skin tissues, inflammatory cytokine expression, and distribution of T lymphocyte subsets in peripheral blood of mice were detected. Expression patterns of IL-9, IL-10, STAT3, JAK2, and INF-γ in clinical samples and mice were detected by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. The positive rate of autologous serum skin test and the histamine release rate of CSU patients, compared with normal subjects, were apparently elevated. Compared with controls, mice with CSU experienced longer duration and higher frequency of pruritus and demonstrated enhanced levels of CD8
Substances chimiques
IFNG protein, human
0
IFNG protein, mouse
0
IL10 protein, human
0
IL10 protein, mouse
0
IL9 protein, human
0
Interleukin-9
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Stat3 protein, mouse
0
Interleukin-10
130068-27-8
Interferon-gamma
82115-62-6
JAK2 protein, human
EC 2.7.10.2
Jak2 protein, mouse
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
480-489Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277.
Goldstein S, Gabriel S, Kianifard F, Ortiz B, Skoner DP. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: review of omalizumab clinical trials. Ann Allergy Asthma Immunol. 2017;118(4):500-504.
Criado PR, Antinori LC, Maruta CW, Reis VM. Evaluation of D-dimer serum levels among patients with chronic urticaria, psoriasis and urticarial vasculitis. An Bras Dermatol. 2013;88(3):355-360.
Marques RZ, Criado RF, Machado CDF, Tamanini JM, Mello CV, Speyer C. Correlation between the histopathology of chronic urticaria and its clinical picture. An Bras Dermatol. 2016;91(6):760-763.
Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129(5):1307-1313.
Goh CL, Tan KT. Chronic autoimmune urticaria: where we stand? Indian J Dermatol. 2009;54(3):269-274.
Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8(6):478-486.
Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010;10(6):440-452.
Blank U, Madera-Salcedo IK, Danelli L, et al. Vesicular trafficking and signaling for cytokine and chemokine secretion in mast cells. Front Immunol. 2014;5:453.
Xu Y, Chen G. Mast cell and autoimmune diseases. Mediators Inflamm. 2015;2015:246126.
Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23-63.
Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71-109.
Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75(2):263-274.
O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev. 2008;223:114-131.
Gong F, Pan YH, Huang X, Zhu HY, Jiang DL. From bench to bedside: therapeutic potential of interleukin-9 in the treatment of asthma. Exp Ther Med. 2017;13(2):389-394.
Hultner L, Druez C, Moeller J, et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol. 1990;20(6):1413-1416.
Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci USA. 1988;85(18):6934-6938.
Komar HM, Serpa G, Kerscher C, et al. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Sci Rep. 2017;7(1):1787.
Zhang L, Wang Y, Ma J, et al. Exogenous MSCs ameliorate hypoxia/reoxygenation injury in renal tubular epithelial cells through JAK/STAT signaling pathway-mediated regulation of HMGB1. Am J Transl Res. 2017;9(5):2412-2420.
Yagami A, Furue M, Togawa M, Saito A, Hide M. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2017;44(4):375-385.
Chen T, Guo ZP, Wang WJ, Fu LX, Sun QM, Zhou PM. Increased serum soluble vascular endothelial cadherin levels in patients with chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2017;118(6):704-709.
Kasumagic-Halilovic E, Beslic N, Ovcina-Kurtovic N. Thyroid autoimmunity in patients with chronic urticaria. Med Arch. 2017;71(1):29-31.
Jain S. Pathogenesis of chronic urticaria: an overview. Dermatol Res Pract. 2014;2014(674 709, 1, 10.
Goswami R, Kaplan MH. A brief history of IL-9. J Immunol. 2011;186(6):3283-3288.
Kaplan MH. Th9 cells: differentiation and disease. Immunol Rev. 2013;252(1):104-115.
Erpenbeck VJ, Hohlfeld JM, Volkmann B, et al. Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. J Allergy Clin Immunol. 2003;111(6):1319-1327.
Chang HC, Sehra S, Goswami R, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol. 2010;11(6):527-534.
Purwar R, Schlapbach C, Xiao S, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med. 2012;18(8):1248-1253.
Gerlach K, Hwang Y, Nikolaev A, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15(7):676-686.
Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009;183(11):7169-7177.
Sehra S, Yao W, Nguyen ET, et al. TH9 cells are required for tissue mast cell accumulation during allergic inflammation. J Allergy Clin Immunol. 2015;136(2):433-440.e431.
Petit-Frere C, Dugas B, Braquet P, Mencia-Huerta JM. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology. 1993;79(1):146-151.
Gounni AS, Nutku E, Koussih L, et al. IL-9 expression by human eosinophils: regulation by IL-1beta and TNF-alpha. J Allergy Clin Immunol. 2000;106(3):460-466.
Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol. 2003;170(7):3461-3467.
Zheng R, Qian L, Yu J, Li M, Qian Q. Analysis of the changes in Th9 cells and related cytokines in the peripheral blood of spontaneous urticaria patients. Biomed Rep. 2017;6(6):633-639.
Irinyi B, Aleksza M, Antal-Szalmas P, Sipka S, Hunyadi J, Szegedi A. Cytokine production of CD4+ and CD8+ peripheral T lymphocytes in patients with chronic idiopathic urticaria. Acta Derm Venereol. 2002;82(4):249-253.
Piconi S, Trabattoni D, Iemoli E, et al. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol. 2002;128(1):59-66.
Caproni M, Giomi B, Volpi W, et al. Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol. 2005;114(3):284-292.
Lacy P, Moqbel R. Eokines: synthesis, storage and release from human eosinophils. Mem Inst Oswaldo Cruz. 1997;92(Suppl 2):125-133.
Lamkhioued B, Gounni AS, Aldebert D, et al. Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Ann N Y Acad Sci. 1996;796:203-208.
Han RT, Kim S, Choi K, et al. Asthma-like airway inflammation and responses in a rat model of atopic dermatitis induced by neonatal capsaicin treatment. J Asthma Allergy. 2017;10:181-189.
Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41-101.
Hill N, Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol. 2002;14(6):791-797.
Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol. 2006;71(6):713-721.
Beldi-Ferchiou A, Skouri N, Ben Ali C, et al. Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. PLoS One. 2017;12(4):e0174835.
Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood. 2004;104(12):3712-3721.
Bommert K, Bargou RC, Stuhmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006;42(11):1574-1580.
Chatterjee M, Jain S, Stuhmer T, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood. 2007;109(2):720-728.
Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12(1):9-18.
Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21(1):11-19.
Fan Y, Mao R, Yang J NF-kB, STAT3 signaling pathways collaboratively link inflammation to cancer. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013;4(3):176-185.